Clinical Trial Update: Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating chemotherapy followed by Alemtuzumab for chronic lymphocytic leukemia or prolymphocytic leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Prolymphocytic Leukemia

Drugs mentioned

• Alemtuzumab (Alemtuzumab)

Snippet

Sponsor: German CLL Study Group | Conditions: Prolymphocytic Leukemia | Phase 2 | Status: COMPLETED